Cell Bio-Systems Approves Prototype Design of Liposuction Handle.

SAN DIEGO -- Cell Bio-Systems, Inc. (Pink Sheets:CBSI), a biotechnology company positioned to manufacture and distribute patented, disposable technologies for cosmetic surgery and other living tissue procedures, announced today that it has approved the production design for a disposable liposuction handle to work in conjunction with the company's patented syringe hub adapter.

The handle will have a variety of configurations, including its main configuration for a 60cc connection. Other configurations will include a built-in on/off switch, used for both infiltration and extraction, and a direct cannula connection used mainly in large volume liposuction.

"The strength of Cell Bio-Systems' patents lies in the many existing applications for our products throughout the healthcare industry," said Marc Pilkington, president and CEO of Cell Bio-Systems. "The approval of this handle design will allow our cannulas to be adapted for use in liposuction procedures. It is the first of many adaptations that will take place with our patented syringe connection devices."

According to the American Society of Plastic Surgeons, liposuction was the most popular surgical cosmetic procedure performed in 2003, with more than 384,626 cases in the United States alone. Industry sources project plastic surgery related medical devices to be a $2 billion per year industry by 2007. Cell Bio-Systems believes its products could represent $250 to 300 million in revenue over the next three years.

Cell Bio-Systems has initiated limited production of its flagship instrument, the Super-Luer injector. The company's early products will allow Cell Bio-Systems to establish manufacturing protocols and complete a pending 510K notification to the FDA in support of the company's claims.

The Super Luer will be adapted to manufacture the first affordable, disposable cannula, an enclosed tubular device, currently made from stainless steel, that looks much like a large needle and has been popularized by its use to insert or extract tissue during liposuction and collagen implant procedures. Though re-sterilized, steel cannulas are reused in hundreds of procedures, typically for as long as two years or more. Despite safety concerns and complications regularly ascribed to steel cannulas, no comparable, disposable device currently exists.

About Cell Bio-Systems

Based in San Diego, California, Cell Bio-Systems is the exclusive licensee of two patented syringe connection products that it plans to adapt as disposable devices for liposuction and other Living Tissue Management(TM) procedures. The company is developing an affordable, disposable product line that will fill this void in the cosmetic surgery and living tissue marketplace. The company's patented, groundbreaking technology will increase patient safety and enhance procedural outcomes. Most notably, Cell Bio-Systems devices can be adapted for a variety of procedures, ranging from fat transfers to biopsies to stem cell research. The company ultimately will develop a complete living tissue management system. CBSI shareholders are encouraged to visit www.cellbiosystems.com and to register on the "Investor Relations" page to receive ongoing CBSI news updates.

Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements'' as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. CBSI disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, and changes in our business strategies.